Despite the threatening rhetoric, the early years of the Biden Administration largely followed previous regimes with respect to antitrust enforcement in the life sciences space. Pharmaceutical transactions in particular encounters the expected amount of agency scrutiny, with most proceeding without an extended investigation and, in contrast to deals in the tech space, did not become testing grounds for more novel theories of competitive harm. This trend might be changing just as deal activity icked up in early 2023. Antitrust & Competition co-chairs Arman Oruc and Andrew Lacy, partner Elliot Silver, and associate Charlie Stewart explain more in GCR’s The Guide to Life Sciences.